FDMT on XNAS, Health Care, 4D Molecular Therapeutics, Inc., job postings
Measures activity, not value. Not investment advice.
Revenue jumped to $96.1M, but the net loss hit $200.4M and shares fell 19% in a month.
GoodInstitutional holders rose to 167 from 158 the quarter before
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Industry
Biological products, (no diagnostic substances) (Health Care)
expected around 6 Jan 2027 (an estimate: a year ago it reported on 7 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $4.1M, net loss $78.1M.
31 Dec 2021RevenueNet incomeNet losstallest bar $85.1M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$4.1M
-$78.1M
30 Jun 2026
$3.8M
-$72.9M
31 Mar 2026
$3.0M
-$68.8M
31 Dec 2025
$85.1M
$19.4M
30 Sep 2025
$90K
-$56.9M
30 Jun 2025
$15K
-$54.7M
31 Mar 2025
$14K
-$48.0M
31 Dec 2024
$1K
-$49.7M
30 Sep 2024
$3K
-$43.8M
30 Jun 2024
$5K
-$35.0M
31 Mar 2024
$28K
-$32.4M
31 Dec 2023
–
-$32.3M
30 Sep 2023
$20.2M
-$10.3M
30 Jun 2023
$239K
-$29.6M
31 Mar 2023
$298K
-$28.7M
31 Dec 2022
$1.2M
-$27.4M
30 Sep 2022
$500K
-$25.7M
30 Jun 2022
$162K
-$28.1M
31 Mar 2022
$1.2M
-$26.3M
31 Dec 2021
–
-$25.1M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$96.1M
$120K
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+79952%
+8.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$200.4M
-$209.2M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$2.70
-$3.75
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
70.4%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-226%
–
-98.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-209%
–
-47.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-56.7%
-58.2%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$307.0M
$305.1M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$19.7M
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$287.3M (net cash)
-$305.1M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.06
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
–
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
21.6
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
6.0
8.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
3.0
6.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
1.7
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider buy/sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$1.6M
bought $0, sold $1.6M
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+5.7%
167 13F filers vs 158
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
–
No 13F holdings or share count.
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
–
10.9M shares sold short (30 Oct 2026); no share count in the company's filings in our data
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
10.4
10.9M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-5.5%
11.5M shares sold short in the report before, 10.9M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
53%
53% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 58%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
19
Tracked since 20 Nov 2026
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
Tracking started 20 Nov 2026; the change shows after 30 days.
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
18
18 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
18×
18 articles in the last 7 days; its usual week has 1.
Price $10.23 on 20 Nov 2026, -1.1% over 12 months (12-month range $7.19 to $16.76)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders sold a net $5.3M in the last 12 months (the 12 months before: -$109K).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.Revenue per quarter. Revenue $4.1M in the latest quarter, +4506% on a year earlier.Capital spending per quarter. Capital spending $49K in the latest quarter.Institutional holders (13F filers). 167 13F filers reported holding it in the latest 13F quarter, +35% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.
Quarter ended 31 Mar 2022: $1.2M, -39% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $162K, -99% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $500K, -63% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $1.2M; public on 16 Mar 2023
Quarter ended 31 Mar 2023: $298K, -76% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $239K, +48% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $20.2M, +3941% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Mar 2024: $28K, -91% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $5K, -98% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $3K, -100% on a year earlier; public on 14 Nov 2024
Quarter ended 31 Dec 2024: $1K; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $14K, -50% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $15K, +200% on a year earlier; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $90K, +2900% on a year earlier; public on 11 Nov 2025
Quarter ended 31 Dec 2025: $85.1M, +8508900% on a year earlier; public on 19 Mar 2026
Quarter ended 31 Mar 2026: $3.0M, +21664% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $3.8M, +25107% on a year earlier; public on 14 Aug 2026
Quarter ended 30 Sep 2026: $4.1M, +4506% on a year earlier; public on 13 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $5.1M, +903% on a year earlier; public on 29 Mar 2022
Quarter ended 31 Mar 2022: $6.4M, +899% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $2.1M, +180% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $2.0M, -25% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $1.1M, -79% on a year earlier; public on 16 Mar 2023
Quarter ended 31 Mar 2023: $1.0M, -84% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $805K, -61% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $405K, -79% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $549K, -50% on a year earlier; public on 1 Mar 2024
Quarter ended 31 Mar 2024: $710K, -30% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $349K, -57% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $1.8M, +339% on a year earlier; public on 14 Nov 2024
Quarter ended 31 Dec 2024: $949K, +73% on a year earlier; public on 1 Mar 2025
Quarter ended 30 Jun 2025: $66K, -81% on a year earlier; public on 12 Aug 2025
Quarter ended 30 Sep 2026: $49K; public on 13 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 72; public on 14 Feb 2022
31 Mar 2022 report: 78; public on 16 May 2022
30 Jun 2022 report: 88; public on 15 Aug 2022
30 Sep 2022 report: 84; public on 14 Nov 2022
31 Dec 2022 report: 90; public on 14 Feb 2023
31 Mar 2023 report: 92; public on 15 May 2023
30 Jun 2023 report: 96; public on 14 Aug 2023
30 Sep 2023 report: 104; public on 14 Nov 2023
31 Dec 2023 report: 103; public on 14 Feb 2024
31 Mar 2024 report: 143; public on 15 May 2024
30 Jun 2024 report: 135; public on 14 Aug 2024
30 Sep 2024 report: 132; public on 14 Nov 2024
31 Dec 2024 report: 142; public on 14 Feb 2025
31 Mar 2025 report: 120; public on 15 May 2025
30 Jun 2025 report: 114; public on 14 Aug 2025
30 Sep 2025 report: 124; public on 14 Nov 2025
31 Dec 2025 report: 147; public on 17 Feb 2026
31 Mar 2026 report: 148; public on 15 May 2026
30 Jun 2026 report: 158; public on 14 Aug 2026
30 Sep 2026 report: 167; public on 16 Nov 2026
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is revenue, quarter at $4.1M (30 Sep 2026), 79× its normal quarter; higher than 83% of its own history.
Short interest spike: had 12.1M shares sold short in the 15 May 2026 report, 2.6× the same report last year Public on 28 May 2026.
19 open postings; careers site tracked since 20 Nov 2026. Most in Finance & accounting 21%, Legal, policy & compliance 21%, Operations & administration 16%, Corporate IT 11%.
Two or more unrelated kinds of records unusual within 30 days
19 Mar 2026confirmed
Confirmed across sources Filings + Financials and Short interest and volume
4D Molecular Therapeutics(FDMT): reported revenue of $85.1M for the quarter ended 31 Dec 2025, 85,090× the same quarter last year, while it had 12.0M shares sold short in the 30 Apr 2026 report, 2.4× the same report last year. Two unrelated kinds of activity within 119 days.
Short interest and volume: Short interest spike, became public on 11 Feb 2026
Short interest and volume: Short interest spike, became public on 26 Feb 2026
Short interest and volume: Short interest spike, became public on 11 Mar 2026
Financials: Quarterly revenue change, became public on 19 Mar 2026
Short interest and volume: Short interest spike, became public on 25 Mar 2026
Short interest and volume: Short interest spike, became public on 11 Apr 2026
Short interest and volume: Short interest spike, became public on 25 Apr 2026
Short interest and volume: Short interest spike, became public on 12 May 2026
Short interest and volume: Short interest spike, became public on 28 May 2026
Short interest and volume: Short interest spike, became public on 10 Jun 2026
The quarter ended 31 Dec 2025 against the 8 quarters before it.
this quarterearliernormal: $10KSee the evidence (10 changes)
Short interest and volume: Short interest spike became public on 11 Feb 2026
4D Molecular Therapeutics had 9.3M shares sold short in the 30 Jan 2026 report, 1.3× the same report last year.
This period
9.3M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
534K
How far from its usual level
+5.6
Same report last year
7.4M
History used
1,872 days
the 30 Jan 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Feb 2026
4D Molecular Therapeutics had 9.7M shares sold short in the 13 Feb 2026 report, 1.6× the same report last year.
This period
9.7M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
534K
How far from its usual level
+6.1
Same report last year
6.2M
History used
1,886 days
the 13 Feb 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Mar 2026
4D Molecular Therapeutics had 10.1M shares sold short in the 27 Feb 2026 report, 1.9× the same report last year.
This period
10.1M (the 27 Feb 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
534K
How far from its usual level
+6.7
Same report last year
5.2M
History used
1,900 days
the 27 Feb 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 19 Mar 2026
4D Molecular Therapeutics reported revenue of $85.1M for the quarter ended 31 Dec 2025, 85,090× the same quarter last year.
This period
$85.1M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$10K
Typical spread (median absolute deviation)
$8K
How far from its usual level
+85.1
Same quarter last year
$1K
History used
2,101 days
the quarter ended 31 Dec 20258 earlier quartersnormal: $10K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 25 Mar 2026
4D Molecular Therapeutics had 10.4M shares sold short in the 13 Mar 2026 report, 2.1× the same report last year.
This period
10.4M (the 13 Mar 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
574K
How far from its usual level
+6.5
Same report last year
5.0M
History used
1,914 days
the 13 Mar 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Apr 2026
4D Molecular Therapeutics had 10.9M shares sold short in the 31 Mar 2026 report, 2.1× the same report last year.
This period
10.9M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
612K
How far from its usual level
+6.6
Same report last year
5.1M
History used
1,932 days
the 31 Mar 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Apr 2026
4D Molecular Therapeutics had 11.5M shares sold short in the 15 Apr 2026 report, 2.2× the same report last year.
This period
11.5M (the 15 Apr 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
662K
How far from its usual level
+6.8
Same report last year
5.2M
History used
1,947 days
the 15 Apr 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 May 2026
4D Molecular Therapeutics had 12.0M shares sold short in the 30 Apr 2026 report, 2.4× the same report last year.
This period
12.0M (the 30 Apr 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
701K
How far from its usual level
+6.9
Same report last year
5.0M
History used
1,962 days
the 30 Apr 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 28 May 2026
4D Molecular Therapeutics had 12.1M shares sold short in the 15 May 2026 report, 2.6× the same report last year.
This period
12.1M (the 15 May 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
844K
How far from its usual level
+5.8
Same report last year
4.7M
History used
1,977 days
the 15 May 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Jun 2026
4D Molecular Therapeutics had 12.2M shares sold short in the 29 May 2026 report, 2.8× the same report last year.
This period
12.2M (the 29 May 2026 report)
Normal report (median of 24 earlier)
5.0M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+3.9
Same report last year
4.4M
History used
1,991 days
the 29 May 2026 report24 earlier reportsnormal: 5.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
21 May 2024confirmed
Confirmed across sources Institutional holdings and Short interest and volume
4D Molecular Therapeutics(FDMT): saw 51 13F filers open a new position in the quarter ended 31 Mar 2024, 3.9× the same quarter last year, while it had 9.7M shares sold short in the 14 Jun 2024 report, 2.8× the same report last year. Two unrelated kinds of activity within 105 days.
Short interest and volume: Short interest spike, became public on 25 Apr 2024
Short interest and volume: Short interest spike, became public on 10 May 2024
Institutional holdings: Many funds opening a new position, became public on 15 May 2024
Short interest and volume: Short interest spike, became public on 25 May 2024
Short interest and volume: Short interest spike, became public on 12 Jun 2024
Short interest and volume: Short interest spike, became public on 27 Jun 2024
Short interest and volume: Short interest spike, became public on 11 Jul 2024
Short interest and volume: Short interest spike, became public on 25 Jul 2024
Short interest and volume: Short interest spike, became public on 10 Aug 2024
The quarter ended 31 Mar 2024 against the 8 quarters before it.
this quarterearliernormal: 17.5See the evidence (9 changes)
Short interest and volume: Short interest spike became public on 25 Apr 2024
4D Molecular Therapeutics had 9.8M shares sold short in the 15 Apr 2024 report, 3.1× the same report last year.
This period
9.8M (the 15 Apr 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
385K
How far from its usual level
+11.0
Same report last year
3.2M
History used
1,217 days
the 15 Apr 2024 report24 earlier reportsnormal: 3.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 May 2024
4D Molecular Therapeutics had 9.6M shares sold short in the 30 Apr 2024 report, 3.4× the same report last year.
This period
9.6M (the 30 Apr 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
418K
How far from its usual level
+9.7
Same report last year
2.8M
History used
1,232 days
the 30 Apr 2024 report24 earlier reportsnormal: 3.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 15 May 2024
4D Molecular Therapeutics saw 51 13F filers open a new position in the quarter ended 31 Mar 2024, 3.9× the same quarter last year.
This period
51 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
17.5
Typical spread (median absolute deviation)
5
How far from its usual level
+4.5
Same quarter last year
13
History used
1,186 days
the quarter ended 31 Mar 20248 earlier quartersnormal: 17.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 25 May 2024
4D Molecular Therapeutics had 9.6M shares sold short in the 15 May 2024 report, 3.3× the same report last year.
This period
9.6M (the 15 May 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
440K
How far from its usual level
+9.2
Same report last year
3.0M
History used
1,247 days
the 15 May 2024 report24 earlier reportsnormal: 3.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Jun 2024
4D Molecular Therapeutics had 9.6M shares sold short in the 31 May 2024 report, 3.1× the same report last year.
This period
9.6M (the 31 May 2024 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
440K
How far from its usual level
+9.0
Same report last year
3.1M
History used
1,263 days
the 31 May 2024 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Jun 2024
4D Molecular Therapeutics had 9.7M shares sold short in the 14 Jun 2024 report, 2.8× the same report last year.
This period
9.7M (the 14 Jun 2024 report)
Normal report (median of 24 earlier)
3.8M
Typical spread (median absolute deviation)
482K
How far from its usual level
+8.3
Same report last year
3.4M
History used
1,277 days
the 14 Jun 2024 report24 earlier reportsnormal: 3.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Jul 2024
4D Molecular Therapeutics had 9.9M shares sold short in the 28 Jun 2024 report, 2.8× the same report last year.
This period
9.9M (the 28 Jun 2024 report)
Normal report (median of 24 earlier)
3.9M
Typical spread (median absolute deviation)
718K
How far from its usual level
+5.6
Same report last year
3.5M
History used
1,291 days
the 28 Jun 2024 report24 earlier reportsnormal: 3.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Jul 2024
4D Molecular Therapeutics had 10.3M shares sold short in the 15 Jul 2024 report, 3.3× the same report last year.
This period
10.3M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
3.9M
Typical spread (median absolute deviation)
836K
How far from its usual level
+5.2
Same report last year
3.1M
History used
1,308 days
the 15 Jul 2024 report24 earlier reportsnormal: 3.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Aug 2024
4D Molecular Therapeutics had 9.5M shares sold short in the 31 Jul 2024 report, 3.1× the same report last year.
This period
9.5M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
4.0M
Typical spread (median absolute deviation)
1.0M
How far from its usual level
+3.6
Same report last year
3.1M
History used
1,324 days
the 31 Jul 2024 report24 earlier reportsnormal: 4.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
10 Jun 2026Short interest and volume change
had 12.2M shares sold short in the 29 May 2026 report, 2.8× the same report last year.
Same report last year: 4.4M; its normal report is 5.0M.
See the evidence
This period
12.2M (the 29 May 2026 report)
Normal report (median of 24 earlier)
5.0M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+3.9
Same report last year
4.4M
History used
1,991 days
the 29 May 2026 report24 earlier reportsnormal: 5.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 12.1M shares sold short in the 15 May 2026 report, 2.6× the same report last year.
Same report last year: 4.7M; its normal report is 4.9M.
See the evidence
This period
12.1M (the 15 May 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
844K
How far from its usual level
+5.8
Same report last year
4.7M
History used
1,977 days
the 15 May 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 12.0M shares sold short in the 30 Apr 2026 report, 2.4× the same report last year.
Same report last year: 5.0M; its normal report is 4.9M.
See the evidence
This period
12.0M (the 30 Apr 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
701K
How far from its usual level
+6.9
Same report last year
5.0M
History used
1,962 days
the 30 Apr 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 11.5M shares sold short in the 15 Apr 2026 report, 2.2× the same report last year.
Same report last year: 5.2M; its normal report is 4.9M.
See the evidence
This period
11.5M (the 15 Apr 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
662K
How far from its usual level
+6.8
Same report last year
5.2M
History used
1,947 days
the 15 Apr 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 10.9M shares sold short in the 31 Mar 2026 report, 2.1× the same report last year.
Same report last year: 5.1M; its normal report is 4.9M.
See the evidence
This period
10.9M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
612K
How far from its usual level
+6.6
Same report last year
5.1M
History used
1,932 days
the 31 Mar 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 10.4M shares sold short in the 13 Mar 2026 report, 2.1× the same report last year.
Same report last year: 5.0M; its normal report is 4.9M.
See the evidence
This period
10.4M (the 13 Mar 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
574K
How far from its usual level
+6.5
Same report last year
5.0M
History used
1,914 days
the 13 Mar 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $85.1M for the quarter ended 31 Dec 2025, 85,090× the same quarter last year, while it had 12.0M shares sold short in the 30 Apr 2026 report, 2.4× the same report last year. Two unrelated kinds of activity within 119 days.
See the evidence (10 changes)
Short interest and volume: Short interest spike became public on 11 Feb 2026
4D Molecular Therapeutics had 9.3M shares sold short in the 30 Jan 2026 report, 1.3× the same report last year.
This period
9.3M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
534K
How far from its usual level
+5.6
Same report last year
7.4M
History used
1,872 days
the 30 Jan 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Feb 2026
4D Molecular Therapeutics had 9.7M shares sold short in the 13 Feb 2026 report, 1.6× the same report last year.
This period
9.7M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
534K
How far from its usual level
+6.1
Same report last year
6.2M
History used
1,886 days
the 13 Feb 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Mar 2026
4D Molecular Therapeutics had 10.1M shares sold short in the 27 Feb 2026 report, 1.9× the same report last year.
This period
10.1M (the 27 Feb 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
534K
How far from its usual level
+6.7
Same report last year
5.2M
History used
1,900 days
the 27 Feb 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 19 Mar 2026
4D Molecular Therapeutics reported revenue of $85.1M for the quarter ended 31 Dec 2025, 85,090× the same quarter last year.
This period
$85.1M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$10K
Typical spread (median absolute deviation)
$8K
How far from its usual level
+85.1
Same quarter last year
$1K
History used
2,101 days
the quarter ended 31 Dec 20258 earlier quartersnormal: $10K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 25 Mar 2026
4D Molecular Therapeutics had 10.4M shares sold short in the 13 Mar 2026 report, 2.1× the same report last year.
This period
10.4M (the 13 Mar 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
574K
How far from its usual level
+6.5
Same report last year
5.0M
History used
1,914 days
the 13 Mar 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Apr 2026
4D Molecular Therapeutics had 10.9M shares sold short in the 31 Mar 2026 report, 2.1× the same report last year.
This period
10.9M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
612K
How far from its usual level
+6.6
Same report last year
5.1M
History used
1,932 days
the 31 Mar 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Apr 2026
4D Molecular Therapeutics had 11.5M shares sold short in the 15 Apr 2026 report, 2.2× the same report last year.
This period
11.5M (the 15 Apr 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
662K
How far from its usual level
+6.8
Same report last year
5.2M
History used
1,947 days
the 15 Apr 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 May 2026
4D Molecular Therapeutics had 12.0M shares sold short in the 30 Apr 2026 report, 2.4× the same report last year.
This period
12.0M (the 30 Apr 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
701K
How far from its usual level
+6.9
Same report last year
5.0M
History used
1,962 days
the 30 Apr 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 28 May 2026
4D Molecular Therapeutics had 12.1M shares sold short in the 15 May 2026 report, 2.6× the same report last year.
This period
12.1M (the 15 May 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
844K
How far from its usual level
+5.8
Same report last year
4.7M
History used
1,977 days
the 15 May 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Jun 2026
4D Molecular Therapeutics had 12.2M shares sold short in the 29 May 2026 report, 2.8× the same report last year.
This period
12.2M (the 29 May 2026 report)
Normal report (median of 24 earlier)
5.0M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+3.9
Same report last year
4.4M
History used
1,991 days
the 29 May 2026 report24 earlier reportsnormal: 5.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
19 Mar 2026Financials change
reported revenue of $85.1M for the quarter ended 31 Dec 2025, 85,090× the same quarter last year.
Same quarter last year: $1K; its normal quarter is $10K.
See the evidence
This period
$85.1M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$10K
Typical spread (median absolute deviation)
$8K
How far from its usual level
+85.1
Same quarter last year
$1K
History used
2,101 days
the quarter ended 31 Dec 20258 earlier quartersnormal: $10K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 10.1M shares sold short in the 27 Feb 2026 report, 1.9× the same report last year.
Same report last year: 5.2M; its normal report is 4.9M.
See the evidence
This period
10.1M (the 27 Feb 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
534K
How far from its usual level
+6.7
Same report last year
5.2M
History used
1,900 days
the 27 Feb 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.7M shares sold short in the 13 Feb 2026 report, 1.6× the same report last year.
Same report last year: 6.2M; its normal report is 4.9M.
See the evidence
This period
9.7M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
534K
How far from its usual level
+6.1
Same report last year
6.2M
History used
1,886 days
the 13 Feb 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.3M shares sold short in the 30 Jan 2026 report, 1.3× the same report last year.
Same report last year: 7.4M; its normal report is 4.9M.
See the evidence
This period
9.3M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
534K
How far from its usual level
+5.6
Same report last year
7.4M
History used
1,872 days
the 30 Jan 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.5M shares sold short in the 15 Jan 2026 report, 1.2× the same report last year.
Same report last year: 7.7M; its normal report is 4.9M.
See the evidence
This period
9.5M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
534K
How far from its usual level
+5.8
Same report last year
7.7M
History used
1,857 days
the 15 Jan 2026 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 8.7M shares sold short in the 31 Dec 2025 report, 1.1× the same report last year.
Same report last year: 8.0M; its normal report is 4.9M.
See the evidence
This period
8.7M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
534K
How far from its usual level
+4.8
Same report last year
8.0M
History used
1,842 days
the 31 Dec 2025 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.5M shares sold short in the 31 Jul 2024 report, 3.1× the same report last year.
Same report last year: 3.1M; its normal report is 4.0M.
See the evidence
This period
9.5M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
4.0M
Typical spread (median absolute deviation)
1.0M
How far from its usual level
+3.6
Same report last year
3.1M
History used
1,324 days
the 31 Jul 2024 report24 earlier reportsnormal: 4.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 10.3M shares sold short in the 15 Jul 2024 report, 3.3× the same report last year.
Same report last year: 3.1M; its normal report is 3.9M.
See the evidence
This period
10.3M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
3.9M
Typical spread (median absolute deviation)
836K
How far from its usual level
+5.2
Same report last year
3.1M
History used
1,308 days
the 15 Jul 2024 report24 earlier reportsnormal: 3.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.9M shares sold short in the 28 Jun 2024 report, 2.8× the same report last year.
Same report last year: 3.5M; its normal report is 3.9M.
See the evidence
This period
9.9M (the 28 Jun 2024 report)
Normal report (median of 24 earlier)
3.9M
Typical spread (median absolute deviation)
718K
How far from its usual level
+5.6
Same report last year
3.5M
History used
1,291 days
the 28 Jun 2024 report24 earlier reportsnormal: 3.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.7M shares sold short in the 14 Jun 2024 report, 2.8× the same report last year.
Same report last year: 3.4M; its normal report is 3.8M.
See the evidence
This period
9.7M (the 14 Jun 2024 report)
Normal report (median of 24 earlier)
3.8M
Typical spread (median absolute deviation)
482K
How far from its usual level
+8.3
Same report last year
3.4M
History used
1,277 days
the 14 Jun 2024 report24 earlier reportsnormal: 3.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.6M shares sold short in the 31 May 2024 report, 3.1× the same report last year.
Same report last year: 3.1M; its normal report is 3.7M.
See the evidence
This period
9.6M (the 31 May 2024 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
440K
How far from its usual level
+9.0
Same report last year
3.1M
History used
1,263 days
the 31 May 2024 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.6M shares sold short in the 15 May 2024 report, 3.3× the same report last year.
Same report last year: 3.0M; its normal report is 3.6M.
See the evidence
This period
9.6M (the 15 May 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
440K
How far from its usual level
+9.2
Same report last year
3.0M
History used
1,247 days
the 15 May 2024 report24 earlier reportsnormal: 3.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 51 13F filers open a new position in the quarter ended 31 Mar 2024, 3.9× the same quarter last year, while it had 9.7M shares sold short in the 14 Jun 2024 report, 2.8× the same report last year. Two unrelated kinds of activity within 105 days.
See the evidence (9 changes)
Short interest and volume: Short interest spike became public on 25 Apr 2024
4D Molecular Therapeutics had 9.8M shares sold short in the 15 Apr 2024 report, 3.1× the same report last year.
This period
9.8M (the 15 Apr 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
385K
How far from its usual level
+11.0
Same report last year
3.2M
History used
1,217 days
the 15 Apr 2024 report24 earlier reportsnormal: 3.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 May 2024
4D Molecular Therapeutics had 9.6M shares sold short in the 30 Apr 2024 report, 3.4× the same report last year.
This period
9.6M (the 30 Apr 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
418K
How far from its usual level
+9.7
Same report last year
2.8M
History used
1,232 days
the 30 Apr 2024 report24 earlier reportsnormal: 3.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 15 May 2024
4D Molecular Therapeutics saw 51 13F filers open a new position in the quarter ended 31 Mar 2024, 3.9× the same quarter last year.
This period
51 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
17.5
Typical spread (median absolute deviation)
5
How far from its usual level
+4.5
Same quarter last year
13
History used
1,186 days
the quarter ended 31 Mar 20248 earlier quartersnormal: 17.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 25 May 2024
4D Molecular Therapeutics had 9.6M shares sold short in the 15 May 2024 report, 3.3× the same report last year.
This period
9.6M (the 15 May 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
440K
How far from its usual level
+9.2
Same report last year
3.0M
History used
1,247 days
the 15 May 2024 report24 earlier reportsnormal: 3.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Jun 2024
4D Molecular Therapeutics had 9.6M shares sold short in the 31 May 2024 report, 3.1× the same report last year.
This period
9.6M (the 31 May 2024 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
440K
How far from its usual level
+9.0
Same report last year
3.1M
History used
1,263 days
the 31 May 2024 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Jun 2024
4D Molecular Therapeutics had 9.7M shares sold short in the 14 Jun 2024 report, 2.8× the same report last year.
This period
9.7M (the 14 Jun 2024 report)
Normal report (median of 24 earlier)
3.8M
Typical spread (median absolute deviation)
482K
How far from its usual level
+8.3
Same report last year
3.4M
History used
1,277 days
the 14 Jun 2024 report24 earlier reportsnormal: 3.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Jul 2024
4D Molecular Therapeutics had 9.9M shares sold short in the 28 Jun 2024 report, 2.8× the same report last year.
This period
9.9M (the 28 Jun 2024 report)
Normal report (median of 24 earlier)
3.9M
Typical spread (median absolute deviation)
718K
How far from its usual level
+5.6
Same report last year
3.5M
History used
1,291 days
the 28 Jun 2024 report24 earlier reportsnormal: 3.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Jul 2024
4D Molecular Therapeutics had 10.3M shares sold short in the 15 Jul 2024 report, 3.3× the same report last year.
This period
10.3M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
3.9M
Typical spread (median absolute deviation)
836K
How far from its usual level
+5.2
Same report last year
3.1M
History used
1,308 days
the 15 Jul 2024 report24 earlier reportsnormal: 3.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Aug 2024
4D Molecular Therapeutics had 9.5M shares sold short in the 31 Jul 2024 report, 3.1× the same report last year.
This period
9.5M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
4.0M
Typical spread (median absolute deviation)
1.0M
How far from its usual level
+3.6
Same report last year
3.1M
History used
1,324 days
the 31 Jul 2024 report24 earlier reportsnormal: 4.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
15 May 2024Institutional holdings change
saw 51 13F filers open a new position in the quarter ended 31 Mar 2024, 3.9× the same quarter last year.
Same quarter last year: 13; its normal quarter is 17.5.
See the evidence
This period
51 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
17.5
Typical spread (median absolute deviation)
5
How far from its usual level
+4.5
Same quarter last year
13
History used
1,186 days
the quarter ended 31 Mar 20248 earlier quartersnormal: 17.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 9.6M shares sold short in the 30 Apr 2024 report, 3.4× the same report last year.
Same report last year: 2.8M; its normal report is 3.6M.
See the evidence
This period
9.6M (the 30 Apr 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
418K
How far from its usual level
+9.7
Same report last year
2.8M
History used
1,232 days
the 30 Apr 2024 report24 earlier reportsnormal: 3.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.8M shares sold short in the 15 Apr 2024 report, 3.1× the same report last year.
Same report last year: 3.2M; its normal report is 3.6M.
See the evidence
This period
9.8M (the 15 Apr 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
385K
How far from its usual level
+11.0
Same report last year
3.2M
History used
1,217 days
the 15 Apr 2024 report24 earlier reportsnormal: 3.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.3M shares sold short in the 28 Mar 2024 report, 3.0× the same report last year.
Same report last year: 3.1M; its normal report is 3.5M.
See the evidence
This period
9.3M (the 28 Mar 2024 report)
Normal report (median of 24 earlier)
3.5M
Typical spread (median absolute deviation)
392K
How far from its usual level
+9.9
Same report last year
3.1M
History used
1,199 days
the 28 Mar 2024 report24 earlier reportsnormal: 3.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 8.5M shares sold short in the 15 Mar 2024 report, 3.3× the same report last year.
Same report last year: 2.6M; its normal report is 3.5M.
See the evidence
This period
8.5M (the 15 Mar 2024 report)
Normal report (median of 24 earlier)
3.5M
Typical spread (median absolute deviation)
396K
How far from its usual level
+8.5
Same report last year
2.6M
History used
1,186 days
the 15 Mar 2024 report24 earlier reportsnormal: 3.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 8.3M shares sold short in the 29 Feb 2024 report, 4.0× the same report last year.
Same report last year: 2.1M; its normal report is 3.5M.
See the evidence
This period
8.3M (the 29 Feb 2024 report)
Normal report (median of 24 earlier)
3.5M
Typical spread (median absolute deviation)
355K
How far from its usual level
+9.3
Same report last year
2.1M
History used
1,171 days
the 29 Feb 2024 report24 earlier reportsnormal: 3.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.1M shares sold short in the 15 Feb 2024 report, 3.2× the same report last year.
Same report last year: 2.2M; its normal report is 3.3M.
See the evidence
This period
7.1M (the 15 Feb 2024 report)
Normal report (median of 24 earlier)
3.3M
Typical spread (median absolute deviation)
316K
How far from its usual level
+8.0
Same report last year
2.2M
History used
1,157 days
the 15 Feb 2024 report24 earlier reportsnormal: 3.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $20.2M for the quarter ended 30 Sep 2023, 40× the same quarter last year.
Same quarter last year: $500K; its normal quarter is $860K.
See the evidence
This period
$20.2M (the quarter ended 30 Sep 2023)
Normal quarter (median of 8 earlier)
$860K
Typical spread (median absolute deviation)
$534K
How far from its usual level
+19.3
Same quarter last year
$500K
History used
1,278 days
the quarter ended 30 Sep 20238 earlier quartersnormal: $860K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Showing the newest 40 of 63 entries; narrow the window or the kind of data to see older ones.
Not listed: 128 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001650648
Ticker
FDMT
Domain
4dmoleculartherapeutics.com
Employer name
4D Molecular Therapeutics, Inc. (1 unverified)
Hq location
CA|EMERYVILLE|94608 (1 unverified)
Name
4D Molecular Therapeutics, Inc.
Wikidata
Q124433826
DOL H-1B labor condition applications and PERM certifications47 data points1 Mar 2021 to 12 May 2025
SEC Form 13F institutional holdings216 data points31 Dec 2020 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)90 records11 Sep 2018 to 12 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)420 data points31 Dec 2018 to 30 Sep 2026
SEC Form 4 insider transactions60 records, 220 data points17 Dec 2020 to 20 Oct 2026
FINRA short interest (twice monthly)422 data points15 Dec 2020 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)2986 data points11 Dec 2020 to 20 Nov 2026